Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
+44 1494 818 053

Zenopa’s guidance throughout the recruitment process was excellent. Zenopa demonstrated a high level of industry knowledge, the clients requirements and what was expected of me.
Munya, 2014

Ipsen and Inspiration Biopharmaceuticals amend terms of alliance

21 August 2012 11:15 in Pharmaceutical Company Restructures

Ipsen has announced that it is restructuring its haemophilia-oriented strategic agreement with Inspiration Biopharmaceuticals.

Under the terms of the agreement, Ipsen will pay $30 million (19.03 million pounds) to Inspiration to recover commercial rights to the haemophilia A therapy OBI-1, while also gaining rights to the haemophilia B treatment IB1001.

As a result, Ipsen will record sales of OBI-1 and IB1001 in its drug sales line, while paying mid-teen royalty on OBI-1 sales and a higher double-digit royalty on IB1001's sales to Inspiration.

Other elements of the new agreement include the resetting of certain previous contractual obligations and an investment of $20 million in Inspiration by Ipsen, with the latter company also gaining the right to appoint two additional members to the former's board of directors.

This comes after the companies announced last August that they will be creating a joint haemophilia business unit structure to act as the exclusive sales organisation for all haemophilia products commercialised under the Inspiration brand in Europe.ADNFCR-8000103-ID-801432924-ADNFCR

Other news stories from 21/08/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd